1 min read
Health Canada Approves Lilly’s Mounjaro for Cardiovascular Risk Reduction
The indication applies to adults with type 2 diabetes and established cardiovascular disease, with the decision based on SURPASS-CVOT trial results.

Health Canada approved Eli Lilly and Company’s Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events among adults with type 2 diabetes and established cardiovascular disease.
Results from the SURPASS-CVOT trial formed the basis for the approval.